TY - JOUR
T1 - Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease
AU - Aiko, Naoto
AU - Yamakawa, Hideaki
AU - Iwasawa, Tae
AU - Takemura, Tamiko
AU - Okudela, Koji
AU - Kitamura, Hideya
AU - Hagiwara, Eri
AU - Ikeda, Satoshi
AU - Baba, Tomohisa
AU - Iso, Shinichiro
AU - Yamaguchi, Yukie
AU - Kondo, Yasushi
AU - Kurabayashi, Takayoshi
AU - Ohashi, Kenichi
AU - Sato, Shinji
AU - Ogura, Takashi
N1 - Funding Information:
NA, HY, TI, TT, KO, HK, EH, SI, TB, SI, YY, YK, TK, KO, and SS have no conflicts of interest to report. TO received a research grant from Boehringer Ingelheim Co., Ltd. and honoraria from Boehringer Ingelheim Co., Ltd. and Shionogi & Co., Ltd.
Funding Information:
NA, HY, TI, TT, KO, HK, EH, SI, TB, SI, YY, YK, TK, KO, and SS have no conflicts of interest to report. TO received a research grant from Boehringer Ingelheim Co., Ltd . and honoraria from Boehringer Ingelheim Co., Ltd. and Shionogi & Co., Ltd.
Publisher Copyright:
© 2020 The Japanese Respiratory Society
PY - 2020/5
Y1 - 2020/5
N2 - Background: Myositis and interstitial lung disease (ILD) frequently occur in patients with anti-aminoacyl-tRNA synthetase (ARS) antibodies. Nearly half of ARS-ILD patients have the acute or subacute form of the disease, and one-third of these patients show a deterioration in pulmonary function over the long-term course because of frequent recurrences and refractoriness to therapy. Several reports recently described different characteristics depending on the individual anti-ARS antibodies, and the anti-asparaginyl tRNA synthetase (KS) antibody was strongly linked to ILD rather than to myositis. We therefore hypothesized that KS-ILD may have clinical characteristics that differ from those of other ARS-ILDs. The aim of this study was to clarify the clinical, radiological, and pathological features of KS antibody-positive ILD. Methods: We retrospectively analyzed 19 consecutive patients with KS-ILD who underwent initial clinical measurements and high-resolution computed tomography and pathological assessments. We also analyzed disease behavior based on pulmonary function test results during the follow-up period. Results: Our KS-ILD cohort included patients with dermatomyositis (10.5%), primary Sjögren syndrome (5.3%), and idiopathic ILD (84.2%). Most patients presented with chronic onset (89.5%) and a nonspecific pattern of interstitial pneumonia at each radiological and pathological assessment (89.4% and 85.7%, respectively). The pulmonary function test results showed that the mean changes from the initial %forced vital capacity and %diffusing capacity of the lung for carbon monoxide at 3 years were 3.7% ± 2.9% and 9.35% ± 3.0%, respectively. Conclusions: Most KS-ILD patients showed a tendency for chronic disease onset and long-term stabilization of pulmonary function.
AB - Background: Myositis and interstitial lung disease (ILD) frequently occur in patients with anti-aminoacyl-tRNA synthetase (ARS) antibodies. Nearly half of ARS-ILD patients have the acute or subacute form of the disease, and one-third of these patients show a deterioration in pulmonary function over the long-term course because of frequent recurrences and refractoriness to therapy. Several reports recently described different characteristics depending on the individual anti-ARS antibodies, and the anti-asparaginyl tRNA synthetase (KS) antibody was strongly linked to ILD rather than to myositis. We therefore hypothesized that KS-ILD may have clinical characteristics that differ from those of other ARS-ILDs. The aim of this study was to clarify the clinical, radiological, and pathological features of KS antibody-positive ILD. Methods: We retrospectively analyzed 19 consecutive patients with KS-ILD who underwent initial clinical measurements and high-resolution computed tomography and pathological assessments. We also analyzed disease behavior based on pulmonary function test results during the follow-up period. Results: Our KS-ILD cohort included patients with dermatomyositis (10.5%), primary Sjögren syndrome (5.3%), and idiopathic ILD (84.2%). Most patients presented with chronic onset (89.5%) and a nonspecific pattern of interstitial pneumonia at each radiological and pathological assessment (89.4% and 85.7%, respectively). The pulmonary function test results showed that the mean changes from the initial %forced vital capacity and %diffusing capacity of the lung for carbon monoxide at 3 years were 3.7% ± 2.9% and 9.35% ± 3.0%, respectively. Conclusions: Most KS-ILD patients showed a tendency for chronic disease onset and long-term stabilization of pulmonary function.
KW - Anti-asparaginyl tRNA synthetase (anti-KS) antibody
KW - Anti-synthetase syndrome
KW - Dermatomyositis
KW - Idiopathic interstitial pneumonia
UR - http://www.scopus.com/inward/record.url?scp=85079850437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079850437&partnerID=8YFLogxK
U2 - 10.1016/j.resinv.2019.12.003
DO - 10.1016/j.resinv.2019.12.003
M3 - Article
C2 - 32094078
AN - SCOPUS:85079850437
SN - 2212-5345
VL - 58
SP - 196
EP - 203
JO - Respiratory Investigation
JF - Respiratory Investigation
IS - 3
ER -